N/A N=30 Evaluation of an Absorbable Implant for the Treatment of Nasal Valve Collapse
Nasal Valve Collapse
Primary: Implant-related Adverse Events — 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 InFlux System for Nasal Breathing Improvement
Nasal Airway Obstruction
Primary: Incidence of Unanticipated Serious Adverse Device Effects — 0 events
N/A N=20 Treatment Outcome Using Vivaer Stylus to Treat Nasal Airway Obstruction
Nasal Obstruction
Primary: Change in NOSE Score — -44.5 units on a scale
N/A N=36 A New Treatment for Mechanical Nasal Obstruction
Nasal Obstruction
Primary: Change in Peak Nasal Inspiratory Flow (PNIF) — 28; 24; 13; 27 liters per minute
N/A N=50 Treatment of Nasal Airway Obstruction Using the Aerin Medical Device
Nasal Obstruction
Primary: Improvement in NOSE Score — 54.8 units on a scale — p=<0.0001
N/A N=137 Latera RCT - Latera vs. Sham Control for Lateral Nasal Valve Collapse
Nasal Valve Collapse · Nasal Breathing
Primary: NOSE Responder Rate — 35; 52 Participants — p=0.0001
N/A N=26 Effect of Added Varnum Mouthpiece on Pharyngeal Collapsibility and Sleep Apnea Severity in Mouth Breathers.
Obstructive Sleep Apnea
Primary: Sleep Apnea Severity as Measured by Apnea-hypopnea Index (AHI) — 16.4; 15.8 Events/hour
N/A N=47 Nasal Septal Flap for Donor Site Reconstruction
Nasal Septum Perforation
Primary: Mean Change in Post-operative Remucosalization at the Donor Site — 47.8; 37.8; 49.7; 43.5 percentage of remucosalization
N/A N=39 Quality of Life Impact of Nasal Airway Treatment With Aerin Medical Device
Nasal Obstruction
Primary: Change From Baseline NOSE Score — 53.3; 48.1; 53.5 units on a scale — p=<0.0001
Phase 4 N=42 The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation
Nasal Obstruction
Primary: Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline…
N/A N=122 Study of the AERin Medical Vivaer® ARC Stylus for Nasal AirWAY Obstruction
Nasal Obstruction
Primary: Change in Nasal Obstructive Symptom Evaluation (NOSE) Scores From Baseline to 3 Months — -47.6 score on a scale
N/A N=31 High Velocity Nasal Insufflation (Hi-VNI) Use in Upper Airway Surgery
Upper Airway Surgery
Primary: Surgical Case Completion Rate Using HVNI With or Without Converting to Alternative Mode of Oxygenation — 19; 7; 5 Participants
N/A N=119 Vivaer® Procedure for Treatment of Nasal Airway Obstruction Study
Nasal Airway Obstruction
Primary: Nasal Obstruction Symptom Evaluation (NOSE) Scale - 3 Month Responder Rate — 88.3; 42.5 percentage of participants
N/A N=94 Barrow Nasal Inventory Survey
Pituitary Tumors
Primary: Change in Mean Survey Response From Baseline to 90 Days Post Surgery — 17.3; 13.5 units on a scale — p=0.001
N/A N=174 Comparison of Oxygenation and Ventilation With a Novel Nasal Mask Versus Standard of Care During Colonoscopy
Colonoscopy · Oxygenation · Ventilation
Primary: Time to First Intervention — 10; 19 minutes
N/A N=24 Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation
Vasomotor Rhinitis
Primary: Net Proportional Change in Nasal Airway Resistance — 0.11; 0.04 proportional change (unit-less)
N/A N=32 A Disposable Device NAS to Treat Obstructive Sleep Apnea and Snoring
Obstructive Sleep Apnea · Snoring
Primary: Apnea-Hypopnea Index (AHI) — 30.0 events/hour — p=0.0559
Phase 3 N=91 Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays
Otitis Media, Serous · Negative Middle Ear Pressure · Rhinitis
Primary: Number of Subjects With Complete Normalization of Abnormal Tympanometry, Regardless of Additional Treatment — 7; 12 participants — p=0.18
Phase 3 N=100 Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps
Chronic Sinusitis · Nasal Polyps
Primary: Nasal Obstruction/Congestion Score — 3.62; 3.30; 2.31; 2.62 units on a scale — p=0.1365
Phase 4 N=64 Mask Leak With Nasal Cannula in Noninvasive Positive Pressure Ventilation
Mechanical Ventilation Pressure High
Primary: Face Mask Leak Measured in Liters Per Minute by the Noninvasive Positive Pressure Ventilation Machine — 0; 0 Liters per minute
N/A N=113 Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study
Nasal Obstruction
Primary: The Primary Efficacy Endpoint is the Percent of Treatment Responders — 101 Participants
N/A N=50 Posterior Nasal Nerve (PNN) Rhinitis Study
Chronic Rhinitis
Primary: Change in Reflective Total Nasal Symptom Score (rTNSS) — -5.1 units on a scale — p=<0.0001
Phase 2 N=140 A Pivotal Subjective Sleep Study of a Nasal Dilator (Breathe Right Tan)
Congestion, Nasal
Primary: Change From Baseline in Mean Total Score of the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) for Each Domain (Sleep, Sleep Time, Symptoms on…
N/A N=70 The Vivaer Procedure for Treatment of the Septal Swell Bodies (SWELL)
Nasal Obstruction
Primary: Nasal Obstruction Symptom Evaluation (NOSE) Scale Mean Change — -45.3 score on a scale
N/A N=20 Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) and Short Laryngologic Surgery
Laryngologic Surgical Procedures
Primary: Average Oxygen Saturation by Pulse Oximetry (SpO2) (Primary Anesthesia Outcome) — 93; 98.7 percentage of saturation (SpO2) — p=0.006
Phase 3 N=48 The Nasal Changes Affected by Different Alar Base Suture Techniques After Maxillary LeFort I Osteotomy
Conditions in T74.31 or T76.31
Primary: Soft and Hard Tissue Landmarks Movement — 0.95; -0.5; -0.95; -0.32 mm — p=0.098
Phase 3 N=323 Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
Bilateral Nasal Polyposis
Primary: Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms — -0.26; -0.53; -0.56; -0.67 units on a scale
N/A N=30 Multi-Treatment PNN Modulation for Chronic Rhinitis
Chronic Rhinitis
Primary: Number of Participants With Procedure-related Serious Adverse Events (SAEs) and/or Serious Adverse Device Effects (SADE) — 0 Participants
Phase 2 N=105 Mepolizumab in Nasal Polyposis
Nasal Polyps
Primary: Number of Participants With a Reduced Need for Surgery at Week 25 — 16; 5; 33; 46 Participants — p=0.003
Phase 3 N=407 Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Nasal Polyps
Primary: Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 52 — 0.0; -1.0 Scores on a scale — p=<0.001